$1.48
0.08[5.71%]
At close: Apr 18
$1.48
0[0.00%]
After Hours: 7:51PM EDT
Pacific Biosciences
(NASDAQ:PACB)Pacific Biosciences Stock (NASDAQ:PACB), Analyst Ratings, Price Targets, Predictions
Pacific Biosciences of California Inc has a consensus price target of $7.83, established from looking at the 37 latest analyst ratings. The last 3 analyst ratings were released from Bernstein, Goldman Sachs, and Scotiabank on April 18, 2024. With an average price target of $4.33 between Bernstein, Goldman Sachs, and Scotiabank, there's an implied 192.79% upside for Pacific Biosciences of California Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Bernstein
Goldman Sachs
Scotiabank
TD Cowen
Barclays
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Pacific Biosciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/18/2024 | PACB | Buy Now | Pacific Biosciences | $1.48 | 68.92% | Bernstein | Eve Burstein | $9 → $2.5 | Maintains | Outperform | Get Alert |
| 04/18/2024 | PACB | Buy Now | Pacific Biosciences | $1.48 | 68.92% | Goldman Sachs | Matthew Sykes | $7 → $2.5 | Downgrade | Buy → Neutral | Get Alert |
| 04/18/2024 | PACB | Buy Now | Pacific Biosciences | $1.48 | 440.54% | Scotiabank | Sung Ji Nam | $15 → $8 | Maintains | Sector Outperform | Get Alert |
| 04/17/2024 | PACB | Buy Now | Pacific Biosciences | $1.48 | 68.92% | TD Cowen | Daniel Brennan | $12 → $2.5 | Maintains | Buy | Get Alert |
| 04/10/2024 | PACB | Buy Now | Pacific Biosciences | $1.48 | 102.7% | Barclays | Luke Sergott | $8 → $3 | Maintains | Equal-Weight | Get Alert |
| 04/10/2024 | PACB | Buy Now | Pacific Biosciences | $1.48 | 372.97% | Goldman Sachs | Matthew Sykes | $9 → $7 | Maintains | Buy | Get Alert |
| 02/16/2024 | PACB | Buy Now | Pacific Biosciences | $1.48 | 710.81% | UBS | John Sourbeer | $12.5 → $12 | Maintains | Buy | Get Alert |
| 12/14/2023 | PACB | Buy Now | Pacific Biosciences | $1.48 | — | Guggenheim | Subbu Nambi | — | Initiates | → Neutral | Get Alert |
| 12/14/2023 | PACB | Buy Now | Pacific Biosciences | $1.48 | 643.24% | Stephens & Co. | Mason Carrico | → $11 | Initiates | → Overweight | Get Alert |
| 12/13/2023 | PACB | Buy Now | Pacific Biosciences | $1.48 | — | Wolfe Research | Doug Schenkel | — | Initiates | → Peer Perform | Get Alert |
| 11/17/2023 | PACB | Buy Now | Pacific Biosciences | $1.48 | 575.68% | UBS | John Sourbeer | $13 → $10 | Upgrade | Neutral → Buy | Get Alert |
| 11/06/2023 | PACB | Buy Now | Pacific Biosciences | $1.48 | 440.54% | Piper Sandler | David Westenberg | $9 → $8 | Maintains | Neutral | Get Alert |
| 10/31/2023 | PACB | Buy Now | Pacific Biosciences | $1.48 | 913.51% | Canaccord Genuity | Kyle Mikson | $17 → $15 | Maintains | Buy | Get Alert |
| 10/31/2023 | PACB | Buy Now | Pacific Biosciences | $1.48 | 643.24% | Cantor Fitzgerald | Ross Osborn | $14 → $11 | Upgrade | Neutral → Overweight | Get Alert |
| 10/24/2023 | PACB | Buy Now | Pacific Biosciences | $1.48 | 575.68% | Morgan Stanley | Tejas Savant | $13 → $10 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | PACB | Buy Now | Pacific Biosciences | $1.48 | 508.11% | Piper Sandler | David Westenberg | $13 → $9 | Maintains | Neutral | Get Alert |
| 09/29/2023 | PACB | Buy Now | Pacific Biosciences | $1.48 | 508.11% | Barclays | Luke Sergott | $14 → $9 | Maintains | Equal-Weight | Get Alert |
| 09/28/2023 | PACB | Buy Now | Pacific Biosciences | $1.48 | 643.24% | Bernstein | Eve Burstein | → $11 | Initiates | → Outperform | Get Alert |
| 09/26/2023 | PACB | Buy Now | Pacific Biosciences | $1.48 | 845.95% | Cantor Fitzgerald | Ross Osborn | → $14 | Reiterates | Neutral → Neutral | Get Alert |
FAQ
What is the target price for Pacific Biosciences (PACB)?
The latest price target for Pacific Biosciences (NASDAQ: PACB) was reported by Bernstein on April 18, 2024. The analyst firm set a price target for $2.50 expecting PACB to rise to within 12 months (a possible 68.92% upside). 28 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Pacific Biosciences (PACB)?
The latest analyst rating for Pacific Biosciences (NASDAQ: PACB) was provided by Bernstein, and Pacific Biosciences maintained their outperform rating.
When was the last upgrade for Pacific Biosciences (PACB)?
The last upgrade for Pacific Biosciences of California Inc happened on November 17, 2023 when UBS raised their price target to $10. UBS previously had a neutral for Pacific Biosciences of California Inc.
When was the last downgrade for Pacific Biosciences (PACB)?
The last downgrade for Pacific Biosciences of California Inc happened on April 18, 2024 when Goldman Sachs changed their price target from $7 to $2.5 for Pacific Biosciences of California Inc.
When is the next analyst rating going to be posted or updated for Pacific Biosciences (PACB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pacific Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pacific Biosciences was filed on April 18, 2024 so you should expect the next rating to be made available sometime around April 18, 2025.
Is the Analyst Rating Pacific Biosciences (PACB) correct?
While ratings are subjective and will change, the latest Pacific Biosciences (PACB) rating was a maintained with a price target of $9.00 to $2.50. The current price Pacific Biosciences (PACB) is trading at is $1.48, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.